Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Airway surface hyperviscosity and defective mucociliary transport by IL-17/TNF-α are corrected by β-adrenergic stimulus
Daniela Guidone, … , Isabelle Sermet, Luis J.V. Galietta
Daniela Guidone, … , Isabelle Sermet, Luis J.V. Galietta
Published October 11, 2022
Citation Information: JCI Insight. 2022;7(22):e164944. https://doi.org/10.1172/jci.insight.164944.
View: Text | PDF
Research Article Pulmonology

Airway surface hyperviscosity and defective mucociliary transport by IL-17/TNF-α are corrected by β-adrenergic stimulus

  • Text
  • PDF
Abstract

The fluid covering the surface of airway epithelia represents a first barrier against pathogens. The chemical and physical properties of the airway surface fluid are controlled by the activity of ion channels and transporters. In cystic fibrosis (CF), loss of CFTR chloride channel function causes airway surface dehydration, bacterial infection, and inflammation. We investigated the effects of IL-17A plus TNF-α, 2 cytokines with relevant roles in CF and other chronic lung diseases. Transcriptome analysis revealed a profound change with upregulation of several genes involved in ion transport, antibacterial defense, and neutrophil recruitment. At the functional level, bronchial epithelia treated in vitro with the cytokine combination showed upregulation of ENaC channel, ATP12A proton pump, ADRB2 β-adrenergic receptor, and SLC26A4 anion exchanger. The overall result of IL-17A/TNF-α treatment was hyperviscosity of the airway surface, as demonstrated by fluorescence recovery after photobleaching (FRAP) experiments. Importantly, stimulation with a β-adrenergic agonist switched airway surface to a low-viscosity state in non-CF but not in CF epithelia. Our study suggests that CF lung disease is sustained by a vicious cycle in which epithelia cannot exit from the hyperviscous state, thus perpetuating the proinflammatory airway surface condition.

Authors

Daniela Guidone, Martina Buccirossi, Paolo Scudieri, Michele Genovese, Sergio Sarnataro, Rossella De Cegli, Federico Cresta, Vito Terlizzi, Gabrielle Planelles, Gilles Crambert, Isabelle Sermet, Luis J.V. Galietta

×

Figure 8

Effect of HCO3– transport and CFTR rescue on airway surface properties.

Options: View larger image (or click on image) Download as PowerPoint
Effect of HCO3– transport and CFTR rescue on airway surface properties.
...
The graphs show the results of FRAP experiments on bronchial epithelia that were pretreated for 72 hours with/without IL-17/TNF-α. (A) Data obtained in non-CF and CF bronchial epithelia with HCO3– or Hepes buffered media on the basolateral side (for 3 hours before measurements). (B) Data from experiments in non-CF and CF bronchial epithelia with YS-01 (5 μM) added to the basolateral side for 3 hours before measurements. (C) Results from F508del/F508del CF bronchial epithelia. Where indicated, epithelia were treated with the VX-809 (1 μM) plus VX-445 (5 μM) or vehicle in the last 24 hours before measurements. All epithelia were stimulated with isoproterenol (100 nM, basolateral). *P < 0.05; **P < 0.01; and ***P < 0.001 (Kruskal-Wallis and Dunn’s test). (D) The illustration shows the proposed changes in ion transport that occur when epithelia treated with IL-17/TNF-α are stimulated with the β-adrenergic agonist.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts